BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...to the U.S. and rebrands as a precision therapeutics...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...pressure from activist investor Velan Capital (see “Lantheus Enters Therapeutics with Progenics Takeout” ). Cancer precision therapeutics...
BioCentury | Apr 12, 2019
Company News

Helomics and Viome to study gut microbiome link to ovarian cancer

...cancer treatment and investigate how those changes affect outcomes. Helomics Corp. is a subsidiary of Precision Therapeutics...
BioCentury | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

...Celsius and Scipher Medicine announced series A rounds this year, and aim to develop autoimmune precision therapeutics...
BioCentury | Jun 6, 2018
Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of...
BioCentury | May 18, 2018
Financial News

Third Rock leads $65M A round for Celsius

...Casdin Capital, Alexandria Venture Investments and undisclosed other investors. Celsius aims to discover and develop precision therapeutics...
BioCentury | May 15, 2018
Financial News

Third Rock leads $65M A round for Celsius

...Casdin Capital, Alexandria Venture Investments and undisclosed other investors. Celsius aims to discover and develop precision therapeutics...
BioCentury | Apr 16, 2015
Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...
BioCentury | Nov 17, 2014
Financial News

Helomics completes venture financing

...$60 million Investor: Healthcare Royalty Partners Note: The company recapitalized and changed its name from Precision Therapeutics...
BioCentury | Nov 13, 2014
Company News

Precision Therapeutics recaps, now Helomics

...recapitalized with a $60 million investment from HealthCare Royalty Partners and changed its name from Precision Therapeutics...
Items per page:
1 - 10 of 51
BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...to the U.S. and rebrands as a precision therapeutics...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...pressure from activist investor Velan Capital (see “Lantheus Enters Therapeutics with Progenics Takeout” ). Cancer precision therapeutics...
BioCentury | Apr 12, 2019
Company News

Helomics and Viome to study gut microbiome link to ovarian cancer

...cancer treatment and investigate how those changes affect outcomes. Helomics Corp. is a subsidiary of Precision Therapeutics...
BioCentury | Nov 2, 2018
Targets & Mechanisms

Rethinking definitions of autoimmune disease

...Celsius and Scipher Medicine announced series A rounds this year, and aim to develop autoimmune precision therapeutics...
BioCentury | Jun 6, 2018
Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of...
BioCentury | May 18, 2018
Financial News

Third Rock leads $65M A round for Celsius

...Casdin Capital, Alexandria Venture Investments and undisclosed other investors. Celsius aims to discover and develop precision therapeutics...
BioCentury | May 15, 2018
Financial News

Third Rock leads $65M A round for Celsius

...Casdin Capital, Alexandria Venture Investments and undisclosed other investors. Celsius aims to discover and develop precision therapeutics...
BioCentury | Apr 16, 2015
Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...
BioCentury | Nov 17, 2014
Financial News

Helomics completes venture financing

...$60 million Investor: Healthcare Royalty Partners Note: The company recapitalized and changed its name from Precision Therapeutics...
BioCentury | Nov 13, 2014
Company News

Precision Therapeutics recaps, now Helomics

...recapitalized with a $60 million investment from HealthCare Royalty Partners and changed its name from Precision Therapeutics...
Items per page:
1 - 10 of 51